Histone deacetylase inhibitors antagonize distinct pathways to suppress tumorigenesis of embryonal rhabdomyosarcoma

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Vleeshouwer Neumann, Terra ^a   Phelps, Michael ^a   Bammler, Theo K ^a   MacDonald, James W ^a   Jenkins, Isaac ^b   Chen, Eleanor Y ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFNB1 PROTEIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; NOTCH1 RECEPTOR; ONCOPROTEIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT; EPHRIN B1; TUMOR PROTEIN; ZEBRAFISH PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL MIGRATION; CELL SELF-RENEWAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; EMBRYONAL RHABDOMYOSARCOMA; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; ZEBRA FISH; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; RHABDOMYOSARCOMA, EMBRYONAL;

ANIMALS; DOWN-REGULATION; EPHRIN-B1; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEOPLASM PROTEINS; RECEPTOR, NOTCH1; RHABDOMYOSARCOMA, EMBRYONAL; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 84955443649     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0144320     Document Type: Article

References (57)

1. Bridge JA, Liu J, Qualman SJ, Suijkerbuijk R, Wenger G, Zhang J, et al. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer. 2002; 33(3):310-21. Epub 2002/01/25. doi: 10.1002/gcc.10026 [pii]. PubMed PMID: PMID: 11807989.
2. Goldstein M, Meller I, Issakov J, Orr-Urtreger A. Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors. Neoplasia. 2006; 8(5):332-43. Epub 2006/06/23. doi: 10.1593/neo.05829 PMID: 16790082; PubMed Central PMCID: PMC1592451.
3. Missiaglia E, Selfe J, Hamdi M, Williamson D, Schaaf G, Fang C, et al. Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. Genes Chromosomes Cancer. 2009; 48 (6):455-67. Epub 2009/02/25. doi: 10.1002/gcc.20655 PMID: 19235922.
4. Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell. 2013; 24(6):710-24. doi: 10.1016/j.ccr.2013.11.002 PMID: 24332040; PubMed Central PMCID: PMC3904731.
5. Chen Y, Takita J, Hiwatari M, Igarashi T, Hanada R, Kikuchi A, et al. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes Cancer. 2006; 45(6):583-91. Epub 2006/03/07. doi: 10.1002/gcc.20322 PMID: 16518851.
6. Paulson V, Chandler G, Rakheja D, Galindo RL, Wilson K, Amatruda JF, et al. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer. 2011; 50(6):397-408. Epub 2011/03/18. doi: 10.1002/gcc.20864 PMID: 21412928.
7. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014; 4(2):216-31. doi: 10.1158/2159- 8290.CD-13-0639 PMID: 24436047.
8. Chen EY, DeRan MT, Ignatius MS, Grandinetti KB, Clagg R, McCarthy KM, et al. Glycogen synthase kinase 3 inhibitors induce the canonical WNT/beta-catenin pathway to suppress growth and selfrenewal in embryonal rhabdomyosarcoma. Proc Natl Acad Sci U S A. 2014; 111(14):5349-54. doi: 10. 1073/pnas.1317731111 PMID: 24706870; PubMed Central PMCID: PMC3986146.
9. Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol. 2012; 90(1):85-94. Epub 2011/11/30. doi: 10.1038/icb.2011.100 PMID: 22124371.
10. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014; 124(1):30-9. Epub 2014/01/03. doi: 10.1172/JCI69738 PMID: 24382387; PubMed Central PMCID: PMC3871231.
11. Jain S, Zain J. Romidepsin in the treatment of cutaneous T-cell lymphoma. J Blood Med. 2011; 2:37-47. doi: 10.2147/JBM.S9649 PMID: 22287862; PubMed Central PMCID: PMC3262342.
12. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007; 12(10):1247-52. doi: 10. 1634/theoncologist.12-10-1247 PMID: 17962618.
13. Blattmann C, Oertel S, Ehemann V, Thiemann M, Huber PE, Bischof M, et al. Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys. 2010; 78(1):237-45. doi: 10.1016/j.ijrobp.2010.03.010 PMID: 20646843.
14. Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA, Marks PA, et al. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res. 2003; 9(15):5749-55. PubMed PMID: PMID: 14654560.
15. Abraham J, Nunez-Alvarez Y, Hettmer S, Carrio E, Chen HI, Nishijo K, et al. Lineage of origin in rhabdomyosarcoma informs pharmacological response. Genes Dev. 2014; 28(14):1578-91. doi: 10.1101/gad.238733.114 PMID: 25030697; PubMed Central PMCID: PMC4102765.
16. Walter D, Satheesha S, Albrecht P, Bornhauser BC, D'Alessandro V, Oesch SM, et al. CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS One. 2011; 6(5):e19506. doi: 10.1371/journal.pone.0019506 PMID: 21602936; PubMed Central PMCID: PMC3094354.
17. Ignatius MS, Chen E, Elpek NM, Fuller AZ, Tenente IM, Clagg R, et al. In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. Cancer Cell. 2012; 21(5):680-93. doi: 10.1016/j.ccr.2012.03.043 PMID: 22624717; PubMed Central PMCID: PMC3381357.
18. Langenau DM, Keefe MD, Storer NY, Guyon JR, Kutok JL, Le X, et al. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev. 2007; 21(11):1382-95. doi: 10.1101/gad.1545007 PMID: 17510286; PubMed Central PMCID: PMC1877750.
19. Belyea BC, Naini S, Bentley RC, Linardic CM. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis. Clin Cancer Res. 2011; 17(23):7324-36. doi: 10.1158/1078-0432. CCR-11-1004 PMID: 21948088; PubMed Central PMCID: PMC3241994.
20. Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome. Genet Med. 2004; 6(6):530-9. PMID: 15545751.
21. Hatley ME, Tang W, Garcia MR, Finkelstein D, Millay DP, Liu N, et al. A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. Cancer Cell. 2012; 22(4):536-46. doi: 10.1016/j.ccr.2012. 09.004 PMID: 23079662; PubMed Central PMCID: PMC3479681.
22. Davy A, Aubin J, Soriano P. Ephrin-B1 forward and reverse signaling are required during mouse development. Genes Dev. 2004; 18(5):572-83. doi: 10.1101/gad.1171704 PMID: 15037550; PubMed Central PMCID: PMC374238.
23. Egea J, Klein R. Bidirectional Eph-ephrin signaling during axon guidance. Trends Cell Biol. 2007; 17 (5):230-8. doi: 10.1016/j.tcb.2007.03.004 PMID: 17420126.
24. Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol. 2005; 6 (6):462-75. doi: 10.1038/nrm1662 PMID: 15928710.
25. Gao Q, Liu W, Cai J, Li M, Gao Y, Lin W, et al. EphB2 promotes cervical cancer progression by inducing epithelial-mesenchymal transition. Hum Pathol. 2014; 45(2):372-81. doi: 10.1016/j.humpath.2013.10. 001 PMID: 24439224.
26. Kandouz M. The Eph/Ephrin family in cancer metastasis: communication at the service of invasion. Cancer Metastasis Rev. 2012; 31(1-2):353-73. doi: 10.1007/s10555-012-9352-1 PMID: 22549394.
27. Petty A, Myshkin E, Qin H, Guo H, Miao H, Tochtrop GP, et al. A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One. 2012; 7(8):e42120. doi: 10.1371/journal.pone.0042120 PMID: 22916121; PubMed Central PMCID: PMC3419725.
28. Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H, et al. Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol. 2009; 174(2):550-64. doi: 10.2353/ajpath.2009.080631 PMID: 19147825; PubMed Central PMCID: PMC2630563.
29. Williamson D, Missiaglia E, de Reynies A, Pierron G, Thuille B, Palenzuela G, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(13):2151-8. doi: 10.1200/JCO.2009.26.3814 PMID: 20351326.
30. Stone RM, Maguire M, Goldberg MA, Antin JH, Rosenthal DS, Mayer RJ. Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood. 1988; 71(3):690-6. PubMed PMID: PMID: 3422828.
31. Azzi S, Bruno S, Giron-Michel J, Clay D, Devocelle A, Croce M, et al. Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. J Natl Cancer Inst. 2011; 103(24):1884-98. doi: 10. 1093/jnci/djr451 PMID: 22043039.
32. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, Berger AJ, et al. Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A. 2009; 106(4):1193-8. doi: 10.1073/pnas. 0811902106 PMID: 19144919; PubMed Central PMCID: PMC2626610.
33. Rephaeli A, Blank-Porat D, Tarasenko N, Entin-Meer M, Levovich I, Cutts SM, et al. In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer. Int J Cancer. 2005; 116(2):226-35. doi: 10.1002/ijc.21030 PMID: 15800932
34. Charytonowicz E, Terry M, Coakley K, Telis L, Remotti F, Cordon-Cardo C, et al. PPARgamma agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. J Clin Invest. 2012; 122(3):886-98. doi: 10.1172/JCI60015 PMID: 22293175; PubMed Central PMCID: PMC3287226.
35. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999; 96(7):3951-6. PubMed PMID: PMID: 10097144; PubMed Central PMCID: PMC22401.
36. Haydon RC, Zhou L, Feng T, Breyer B, Cheng H, Jiang W, et al. Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res. 2002; 8(5):1288-94. PubMed PMID: PMID: 12006550.
37. Tapscott SJ, Thayer MJ, Weintraub H. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science. 1993; 259(5100):1450-3. PubMed PMID: PMID: 8383879.
38. Yang Z, MacQuarrie KL, Analau E, Tyler AE, Dilworth FJ, Cao Y, et al. MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state. Genes Dev. 2009; 23(6):694-707. doi: 10.1101/gad.1765109 PMID: 19299559; PubMed Central PMCID: PMC2661613.
39. Satheesha S, Manzella G, Bovay A, Casanova EA, Bode PK, Belle R, et al. Targeting hedgehog signaling reduces self-renewal in embryonal rhabdomyosarcoma. Oncogene. 2015. doi: 10.1038/onc.2015. 267 PMID: 26189795.
40. Gerber AN, Wilson CW, Li YJ, Chuang PT. The hedgehog regulated oncogenes Gli1 and Gli2 block myoblast differentiation by inhibiting MyoD-mediated transcriptional activation. Oncogene. 2007; 26 (8):1122-36. doi: 10.1038/sj.onc.1209891 PMID: 16964293; PubMed Central PMCID: PMCPMC3325095.
41. Uhmann A, Niemann H, Lammering B, Henkel C, Hess I, Rosenberger A, et al. Calcitriol inhibits hedgehog signaling and induces vitamin d receptor signaling and differentiation in the patched mouse model of embryonal rhabdomyosarcoma. Sarcoma. 2012; 2012:357040. doi: 10.1155/2012/357040 PMID: 22550417; PubMed Central PMCID: PMCPMC3329653.
42. Raimondi L, Ciarapica R, De Salvo M, Verginelli F, Gueguen M, Martini C, et al. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo. Cell Death Differ. 2012; 19(5):871-81. doi: 10.1038/cdd.2011.171 PMID: 22117196; PubMed Central PMCID: PMCPMC3321627.
43. De Salvo M, Raimondi L, Vella S, Adesso L, Ciarapica R, Verginelli F, et al. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells. PloS one. 2014; 9(5):e96238. doi: 10. 1371/journal.pone.0096238 PMID: 24797362; PubMed Central PMCID: PMCPMC4010457.
44. Boyd AW, Bartlett PF, Lackmann M. Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov. 2014; 13(1):39-62. doi: 10.1038/nrd4175 PMID: 24378802.
45. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 2010; 10(3):165-80. doi: 10.1038/nrc2806 PMID: 20179713; PubMed Central PMCID: PMC2921274.
46. Chiappalupi S, Riuzzi F, Fulle S, Donato R, Sorci G. Defective RAGE activity in embryonal rhabdomyosarcoma cells results in high PAX7 levels that sustain migration and invasiveness. Carcinogenesis. 2014; 35(10):2382-92. doi: 10.1093/carcin/bgu176 PMID: 25123133.
47. Clifford N, Smith LM, Powell J, Gattenlohner S, Marx A, O'Connor R. The EphA3 receptor is expressed in a subset of rhabdomyosarcoma cell lines and suppresses cell adhesion and migration. J Cell Biochem. 2008; 105(5):1250-9. doi: 10.1002/jcb.21926 PMID: 18814179.
48. Aslam MI, Abraham J, Mansoor A, Druker BJ, Tyner JW, Keller C. PDGFRbeta reverses EphB4 signaling in alveolar rhabdomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111(17):6383-8. doi: 10.1073/pnas.1403608111 PMID: 24733895; PubMed Central PMCID: PMCPMC4035936.
49. Berardi AC, Marsilio S, Rofani C, Salvucci O, Altavista P, Perla FM, et al. Up-regulation of EphB and ephrin-B expression in rhabdomyosarcoma. Anticancer Res. 2008; 28(2A):763-9. PubMed PMID: PMID: 18507018.
50. Lopez-Atalaya JP, Ito S, Valor LM, Benito E, Barco A. Genomic targets, and histone acetylation and gene expression profiling of neural HDAC inhibition. Nucleic acids research. 2013; 41(17):8072-84. doi: 10.1093/nar/gkt590 PMID: 23821663; PubMed Central PMCID: PMC3783173.
51. Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell. 2009; 138(5):1019-31. doi: 10. 1016/j.cell.2009.06.049 PMID: 19698979; PubMed Central PMCID: PMC2750862.
52. Hedrick E, Crose L, Linardic CM, Safe S. Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors. Mol Cancer Ther. 2015; 14(9):2143-53. doi: 10.1158/1535-7163.MCT-15-0148 PMID: 26162688.
53. Chen EY, Dobrinski KP, Brown KH, Clagg R, Edelman E, Ignatius MS, et al. Cross-species array comparative genomic hybridization identifies novel oncogenic events in zebrafish and human embryonal rhabdomyosarcoma. PLoS genetics. 2013; 9(8):e1003727. doi: 10.1371/journal.pgen.1003727 PMID: 24009521; PubMed Central PMCID: PMC3757044.
54. Mizgireuv IV, Revskoy SY. Transplantable tumor lines generated in clonal zebrafish. Cancer Res. 2006; 66(6):3120-5. doi: 10.1158/0008-5472.CAN-05-3800 PMID: 16540662.
55. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004; 3:Article3. doi: 10.2202/1544-6115.1027 PMID: 16646809.
56. Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing. Bioinformatics. 2010; 26(19):2363-7. doi: 10.1093/bioinformatics/btq431 PMID: 20688976; PubMed Central PMCID: PMC2944196.
57. Ritchie ME, Diyagama D, Neilson J, van Laar R, Dobrovic A, Holloway A, et al. Empirical array quality weights in the analysis of microarray data. BMC Bioinformatics. 2006; 7:261. doi: 10.1186/1471-2105- 7-261 PMID: 16712727; PubMed Central PMCID: PMC1564422.